- Home
- KRNT vs VRDN Comparison
KRNT vs VRDN Comparison
Compare KRNT & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRNT
- VRDN
- Stock Information
- Founded
- KRNT 2002
- VRDN 2006
- Country
- KRNT Israel
- VRDN United States
- Employees
- KRNT N/A
- VRDN N/A
- Industry
- KRNT Industrial Machinery/Components
- VRDN Medical Specialities
- Sector
- KRNT Industrials
- VRDN Health Care
- Exchange
- KRNT Nasdaq
- VRDN Nasdaq
- Market Cap
- KRNT 1.5B
- VRDN 1.5B
- IPO Year
- KRNT 2015
- VRDN N/A
- Fundamental
- Price
- KRNT $31.03
- VRDN $20.14
- Analyst Decision
- KRNT Strong Buy
- VRDN Strong Buy
- Analyst Count
- KRNT 4
- VRDN 10
- Target Price
- KRNT $29.00
- VRDN $37.25
- AVG Volume (30 Days)
- KRNT 314.8K
- VRDN 1.1M
- Earning Date
- KRNT 11-06-2024
- VRDN 11-12-2024
- Dividend Yield
- KRNT N/A
- VRDN N/A
- EPS Growth
- KRNT N/A
- VRDN N/A
- EPS
- KRNT N/A
- VRDN N/A
- Revenue
- KRNT $199,714,000.00
- VRDN $302,000.00
- Revenue This Year
- KRNT N/A
- VRDN N/A
- Revenue Next Year
- KRNT $10.34
- VRDN N/A
- P/E Ratio
- KRNT N/A
- VRDN N/A
- Revenue Growth
- KRNT N/A
- VRDN N/A
- 52 Week Low
- KRNT $13.59
- VRDN $11.40
- 52 Week High
- KRNT $33.00
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- KRNT 70.77
- VRDN 36.38
- Support Level
- KRNT $29.40
- VRDN $22.40
- Resistance Level
- KRNT $33.00
- VRDN $27.20
- Average True Range (ATR)
- KRNT 1.39
- VRDN 1.36
- MACD
- KRNT 0.60
- VRDN -0.41
- Stochastic Oscillator
- KRNT 81.55
- VRDN 6.37
About KRNT Kornit Digital Ltd.
Kornit Digital Ltd develops, designs and markets digital printing solutions for the world-wide printed textile industry. The company focuses on its DTG and DTF segments of the printed textile industry. Its solutions include digital printing systems, ink and other consumables, associated software and value-added services that allow for large-scale printing of short runs of complex images and designs directly on finished garments and fabrics. It generates revenue from sales of systems, ink and other consumables and service including software subscriptions The company geographically operates in U.S., EMEA, Asia Pacific and other countries. It derives maximum revenue from U.S.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.